BASKING RIDGE, N.J. , July 15, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has filed a "universal shelf" registration statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange
ROCKAWAY, N.J. , Feb. 28, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distributor of the
ROCKAWAY, NJ , Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30,
Third quarter 2020 Revenue expected to exceed $1 million , representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019 Operating cash burn for the third quarter 2020 of approximately $4.1 million BASKING RIDGE, N.J. , Oct.
BASKING RIDGE, N.J. , July 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the second quarter and full year 2020.
Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M ; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020 of $3.7 million , compares favorably to previously announced guidance of $4M December 31,
BASKING RIDGE, N.J. , April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020.
First-quarter 2021 revenue expected to be more than $1.1 million Net cash used for the first quarter 2021 of approximately $4.1 million ROCKAWAY, NJ , April 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an
Record r evenue from product sales will be approximately $1.9M ; approximately 60% growth over first quarter 2021 March 31, 2022 , cash balance of approximately $29.9M ROCKAWAY, N.J. , April 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage
Second-Quarter 2021 revenue expected to be approximately $ 1.3 million Net cash used to fund operations in the second quarter 2021 of approximately $ 3.2 million Follow on offering subsequent to June 30, 2021 added $18 . 8 million to cash balance ROCKAWAY, NJ , July 13, 2021 (GLOBE NEWSWIRE)